EMETE-CON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emete-con, and what generic alternatives are available?
Emete-con is a drug marketed by Pfizer and Roerig and is included in two NDAs.
The generic ingredient in EMETE-CON is benzquinamide hydrochloride. Additional details are available on the benzquinamide hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMETE-CON?
- What are the global sales for EMETE-CON?
- What is Average Wholesale Price for EMETE-CON?
Summary for EMETE-CON
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Patent Applications: | 1,596 |
| DailyMed Link: | EMETE-CON at DailyMed |
US Patents and Regulatory Information for EMETE-CON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | EMETE-CON | benzquinamide hydrochloride | INJECTABLE;INJECTION | 016820-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Roerig | EMETE-CON | benzquinamide hydrochloride | SUPPOSITORY;RECTAL | 016818-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
